Single-microglia transcriptomic transition network-based prediction and real-world patient data validation identifies ketorolac as a repurposable drug for Alzheimer’s disease.
High microglial heterogeneities hinder the development of microglia-targeted treatment for Alzheimer’s disease (AD).